Abeona Therapeutics Q2 net loss widens, misses analyst expectations

Abeona Therapeutics

13/08/2026 12:39

Overview
US cell and gene therapy firm's Q2 net ZEVASKYN revenue rose 31% quarter-over-quarter
Q2 net loss and loss per share missed analyst expectations
Q2 income from operations was slightly better than analyst expectations

Outlook
Abeona anticipates broader adoption and long-term growth as real-world experience with ZEVASKYN matures

Result Drivers
PATIENT TREATMENTS - Q2 revenue growth attributed to increased number of patients treated with ZEVASKYN
QTC NETWORK EXPANSION - Co said expanding qualified treatment center network enabled more patient onboarding and treatments
MANUFACTURING YIELD - Revenue not recognized for some treatments due to low manufacturing yield or not meeting lot release specifications

Company press release: ID:nGNX6NbWXd

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
Miss
$0.35
$0.23 (7 Analysts)
Q2 Net Loss
Miss
$20.19 mln
$13.23 mln (7 Analysts)
Q2 Income From Operations
Beat
-$13.65 mln
-$14.49 mln (7 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Abeona Therapeutics Inc is $20.00, about 168.1% above its August 12 closing price of $7.46

Reuters Recommended Reads
Aug 12 - Century Therapeutics Q2 net loss misses estimates on lease termination loss
Aug 11 - Taysha Gene Therapies Q2 net loss widens on higher R&D costs
Aug 10 - Rocket Pharmaceuticals posts Q2 profit helped by PRV sale

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)